
    
      The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase
      3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%)
      Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental
      Exposure Chamber (EEC).
    
  